Search Results

New partners reinvigorate a once-touted cancer treatment.

• Authors : Leslie M

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

• Source: Science (New York, N.Y.) [Science] 2023 May 19; Vol. 380 (6646), pp. 679-680. Date of Electronic Publication: 2023 May 18.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic

Record details

Angiogenesis inhibitors suffer new setback.

• Authors : Garber K

Subjects: Drug Approval*; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*adverse effects ; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use

• Source: Nature biotechnology [Nat Biotechnol] 2002 Nov; Vol. 20 (11), pp. 1067-8.Publisher: Nature America Publishing Country of Publication: United States NLM ID: 9604648 Publication Model: Print Cited Medium: Print ISSN:

Record details

FDA. Once on 'fast track,' avastin now derailed.

• Authors : Couzin-Frankel J; Ogale Y

Subjects: Drug Approval* ; United States Food and Drug Administration*; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use

• Source: Science (New York, N.Y.) [Science] 2011 Jul 08; Vol. 333 (6039), pp. 143-4.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details

Cancer therapy. Setbacks for endostatin.

• Authors : Marshall E

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*administration & dosage ; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage

• Source: Science (New York, N.Y.) [Science] 2002 Mar 22; Vol. 295 (5563), pp. 2198-9.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details

Cancer. Encouraging results for second-generation antiangiogenesis drugs.

• Authors : Marx J

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use

• Source: Science (New York, N.Y.) [Science] 2005 May 27; Vol. 308 (5726), pp. 1248-9.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details

Good news about new macular degeneration drugs.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Macular Degeneration/Macular Degeneration/Macular Degeneration/*drug therapy

• Source: Harvard health letter [Harv Health Lett] 2011 Jan; Vol. 36 (3), pp. 7.Publisher: Harvard Medical School Health Publications Group Country of Publication: United States NLM ID: 9425764 Publication Model: Print Cited Medium:

Record details

Angiogenesis research. Cancer drugs found to work in new way.

• Authors : Barinaga M

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Neoplasms/Neoplasms/Neoplasms/*drug therapy

• Source: Science (New York, N.Y.) [Science] 2000 Apr 14; Vol. 288 (5464), pp. 245.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details

PEDF: bridging neurovascular interactions in the stem cell niche.

• Authors : Pumiglia K; Temple S

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*metabolism ; Blood Vessels/Blood Vessels/Blood Vessels/*metabolism ; Brain/Brain/Brain/*metabolism

• Source: Nature neuroscience [Nat Neurosci] 2006 Mar; Vol. 9 (3), pp. 299-300.Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9809671 Publication Model: Print Cited Medium: Print ISSN:

Record details

Your health in the 21st century. The next revolution.

• Authors : Folkman J

Subjects: Angiogenesis Inhibitors* ; Biomedical Research*; Neoplasms/Neoplasms/Neoplasms/*drug therapy

• Source: Newsweek [Newsweek] 2005 Summer; Vol. 145 (26A), pp. 21.Publisher: Newsweek, Inc Country of Publication: United States NLM ID: 9877127 Publication Model: Print Cited Medium: Print ISSN: 0028-9604

Record details

Cancer research. Obstacle for promising cancer therapy.

• Authors : Marx J

Subjects: Cell Hypoxia* ; Gene Silencing* ; Genes, p53*

• Source: Science (New York, N.Y.) [Science] 2002 Feb 22; Vol. 295 (5559), pp. 1444.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details